Letter from Professor Robert A. Kyle, MD
XIV International Conference: “Complex Treatment of Plasma Cell Dyscrasias in 2026” at the Jagiellonian University Medical College, St. Anna 12, 31-008 Krakow, September 4-5, 2026.
This up-to-date and important conference has been organized by Professor Artur Jurczyszyn of the Jagiellonian University Medical College in Krakow, Poland.
There will be a Welcome Dinner on Friday, September 4, 2026, at 7:00 p.m. at the Wierzynek Restaurant. Professors Maciej Małecki and Artur Jurczyszyn will open the conference at 12:00 p.m. on Saturday, September 5, 2026.
The chairmen of Session I consist of Professors Wiesław W. Jedrzejczak, Aleksander B. Skotnicki, and Dr. Wojciech Legiec.
The first speaker is Professor Gosta Gahrton, Karolinska Institut, Sweden, on “History of Treatment of Multiple Myeloma.”
Professor Hermann Einsele, University Hospital of Wurzburg, Germany, will follow with a presentation on “CAR-T Cells in Myeloma: Current Practice and Future Developments.” Professor Morie A. Gertz, Mayo Clinic, USA, will present an address entitled “Why High-Risk Smoldering
Multiple Myeloma Should Not Be Treated Outside of a Clinical Trial.”
Professor David H. Vesole, Hackensack University Medical Center, New Jersey Medical School, Rutgers University, New Jersey, USA, with a presentation “Bispecific T-Cell Engager Therapy for Multiple Myeloma.”
Following the coffee break, the chairmen of Session II are Professor Tomasz Sacha, dr hab. n. med. Grzegorz Charliński, and Dr. Pawel Steckiewicz.
The first presentation of Session II is Professor Ghulam Rehman Mohyuddin, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA, who will speak on “Quality of Life in Multiple Myeloma in 2026.” Professor Attaya Suvannasankha, Indiana University Melvin and Bren
Simon Comprehensive Cancer Center, USA, will then speak on “Advances in Systemic AL Amyloidosis.” Professor Joshua Richter, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA, will present on “Practical Aspects of Immunotherapy in Multiple
Myeloma in 2026.”Followed by a presentation by Professor Rahul Banerjee, Fred Hutchinson Cancer Center, Seattle, WA, USA, who will speak on “How I Define and Treat High-Risk Multiple Myeloma.”
The afternoon session will close with “Advances in Supportive Care for Multiple Myeloma in 2026” by the host, Professor Artur Jurczyszyn.
The sessions will be followed by a dinner at Collegium Maius, 31-010 Krakow, Jagiellonska 15 at 7:00 p.m.
This conference will update the attendees on History of Treatment of Multiple Myeloma, CAR-T Cells in Myeloma: Current Practice and Future Developments, Why High-Risk Smoldering Multiple Myeloma Should Not Be Treated Outside of a Clinical Trial, Bispecific T-Cell Engager
Therapy for Multiple Myeloma, Quality of Life in Multiple Myeloma in 2026, Advances in Systemic AL Amyloidosis, Practical Aspects of Immunotherapy in Multiple Myeloma in 2026, How I Define and Treat High-Risk Multiple Myeloma, and Advances in Supportive Care for Multiple
Myeloma in 2026.
Robert A. Kyle, MD, MACP
Professor of Medicine
Emeritus, Retired – 2023
Mayo Clinic
Rochester, MN
